Lv3
228 积分 2022-08-09 加入
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
18小时前
已完结
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF -Mutated Colorectal Cancer
1个月前
已完结
Global radiotherapy demands and corresponding radiotherapy-professional workforce requirements in 2022 and predicted to 2050: a population-based study
1个月前
已完结
Targeting EZH2 for cancer therapy: From current progress to novel strategies
2个月前
已完结
RAF inhibitors that evade paradoxical MAPK pathway activation
2个月前
已完结
Trough to peak ratio: current status and applicability
3个月前
已完结
Analysis of China-to-West pharmaceutical licensing deals in 2024
3个月前
已关闭
DDR1-targeted therapies: current limitations and future potential
4个月前
已完结
Research progress of DDR1 inhibitors in the treatment of multiple human diseases
4个月前
已完结
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma
5个月前
已完结
皖公网安备34019202002308
